GLP-1 medicine are studied in a rising variety of indications, and Novo Nordisk can now declare to have authorised the primary remedy on this class for continual kidney illness. The FDA has expanded the Ozempic label and authorised the Novo Nordisk product for lowering the danger of worsening kidney illness and kidney failure and lowering the danger of demise. The […]